Cooperative Agreement U01CA288351
Award Date
8/12/24
Completion Date
7/31/29
Dollars Obligated
$641K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Cooperative Agreement
Place of Performance
Irvine, CA 92697, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Emory University aims to establish an innovative platform for conformal flash proton therapy in the treatment of central lung cancer. The $158,899 award, spanning June 2025 to May 2027, will fund the development of a Simultaneous Intensity Energy Modulation and Compensation (SIEMAC) optimization platform to inversely solve for the intensity and energy variables in the integrated...
The National Cancer Institute (NCI) awarded a $399,214 Project Grant under CFDA 93.395 - Cancer Treatment Research to Proton Bio, Inc., a minority-owned business located in Baltimore, Maryland. The grant supports a 12-month project to develop and evaluate a novel therapy targeting the proton-sensing receptor GPR68 as a potential treatment for glioblastoma (GBM), the most common and aggressive form of adult brain cancer. The project will focus on three key objectives: 1) define the in vitro...
The National Cancer Institute (NCI) awarded a $596,095 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Washington. The grant will support the development and validation of the Personalized Remote Radiation Tracking Portable Organ Dosimetry Device (PRRT PODD), a patient-friendly technology that enables personalization of 177Lu-DOTATATE therapy for neuroendocrine tumor patients. The project aims to design compact imaging detectors and software tools for...
The National Cancer Institute (NCI) awarded a $1,003,173 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Radiopharmaceutical Imaging and Dosimetry, LLC to develop a prototype web/cloud-based quantitative SPECT reconstruction software system for clinical trials and dosimetry of radiopharmaceutical therapy (RPT) using alpha-emitting radionuclides. The key objectives are to: 1) improve existing quantitative SPECT methods by enhancing scatter and downscatter modeling and adding partial...
The National Cancer Institute awarded a Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) totaling $568,151 to the Regents of the University of Michigan. The grant will fund research to develop a real-time functional photoacoustic imaging platform with the capability to quantitatively evaluate prostate cancer tumor heterogeneity and microenvironment for improved prostate cancer diagnosis and prognosis. The research aims to optimize photoacoustic-nanoparticle contrast...
This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop an innovative radiation imaging tool to support the advancement of targeted alpha cancer therapies. The $811,503 award to Qscint Imaging Solutions LLC, located in Tucson, AZ, will fund the refinement of an algorithm for real-time isotopic spectroscopy...
This Cooperative Agreement award, provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), aims to develop a novel radiation biodosimetry tool based on autofluorescence imaging. The University of California, Los Angeles (UCLA) will receive $551,250 over the period of July 2025 to May 2030 to conduct this research. The key objectives are to: Determine the dose-response and time course of radiation-induced autofluorescence in vitro, which will...
This federal Project Grant award for $599,191, provided by the National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research program), supports the development and validation of a 3D dynamic contrast-enhanced ultrasound (3D DCE-US) framework to characterize tumor vascular properties for liver malignancies. The goal is to introduce computational approaches that leverage the interconnected nature of voxels in 3D DCE-US imaging to capture new information beyond conventional...
The National Cancer Institute (NCI) awarded a $898,497 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Radiopharmaceutical Imaging and Dosimetry, LLC to develop a cloud-based, customer-responsive dosimetry tool for alpha-particle emitting radiopharmaceutical therapies. The key objectives are to: 1) establish a library of microscale S-values and apportionment factors for dose-limiting tissues, 2) implement a macro-to-micro dosimetry methodology to enable...
This federal Cooperative Agreement award, issued by the Department of the Interior's Interior Business Center under the Advanced Research Projects Agency for Health (ARPA-H) program (CFDA 93.384), supports the development of a novel imaging technology called "VISION" that enables real-time, high-resolution intraoperative detection of microscopic residual cancer cells during surgical procedures. The $5,160,920 award to the Regents of the University of California, San Francisco aims to...